Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP
Regeneron (NASDAQ: REGN) reported 84-week data from the Phase 3 OPTIMA trial showing sustained efficacy of Pasatru in adults with FOP, reducing new HO lesions and flare-ups. The trial met its primary endpoint at 56 weeks, with continued benefits observed at 84 weeks. Pasatru was FDA-approved based on the 56-week trial results. The company plans to initiate a Phase 3 trial in adolescents and children with FOP later this year.
How this was made
The 30-second read
Why it matters
The week 84 re-assessment shows no new HO lesions at week 84 for Pasatru versus new lesions for placebo, and continued reduction in clinician-assessed flare-ups, with a generally consistent safety profile.
Market read
Traders get new durability evidence (CT lesion and flare-up outcomes through week 84) that can influence expectations for regulatory review and long-term adoption.
What to watch
The article emphasizes efficacy and safety, but does not quantify broader commercial endpoints, EU regulatory timing, or any changes to the planned pediatric/adolescent OPTIMA 2 timeline.
Background
Pasatru (garetosmab-grts) is FDA-approved for adults with FOP based on a 56-week placebo-controlled trial; OPTIMA is the Phase 3 program with an extension to at least 84 weeks.
Ticker impact
Regeneron reports positive 84-week Phase 3 OPTIMA results for Pasatru in adult FOP, extending efficacy and safety versus placebo through week 84.
Likely positive bias as traders price in improved durability evidence for an already FDA-approved therapy and potential EU review progress.
The article discloses new week 56 to 84 re-assessment outcomes (CT lesion counts and flare-ups) plus continued safety, which is decision-relevant for biotech valuation even without new FDA action.
Market effects
Reinforces investor appetite for durable efficacy evidence in rare-disease monoclonal antibodies and Activin A pathway programs.
Limited direct regional impact; primarily US-listed biotech sentiment.
Supports global development/regulatory discussions (EU submission under review) for Pasatru.
Counterpoint
Durability data may already be partially anticipated given prior 56-week results, so incremental valuation impact could be muted versus the initial approval reaction.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
US-listed biotech reporting late-breaking 84-week OPTIMA efficacy and safety results for Pasatru in adult FOP.
- drugPasatru (garetosmab-grts)
VelocImmune-derived fully human monoclonal antibody targeting Activin A signaling for FOP.
- clinical_trialOPTIMA trial
Phase 3 randomized, double-blind, placebo-controlled study with extension to at least 84 weeks.
- eventASBMR Annual Meeting
Conference venue where the late-breaking oral session presented the 84-week data.
